Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line

被引:23
作者
Laplante, Yannick [1 ,2 ]
Poirier, Donald [1 ,2 ]
机构
[1] CHUQ Pavillon CHUL, Oncol & Mol Endocrinol Res Ctr, Div Med Chem, Quebec City, PQ G1V 4G2, Canada
[2] Univ Laval, Quebec City, PQ G1V 4G2, Canada
关键词
LNCaP cells; 17; beta-hydroxysteroid; dehydrogenases; 5; alpha-reductases; androgens; androst-4-ene-3,17-dione;
D O I
10.1016/j.steroids.2007.10.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
As a therapeutic approach for the treatment of androgen-sensitive diseases, it would be tempting to lower the level of the potent androgens testosterone (T) and dihydrotestosterone (DHT) by using inhibitors of type 3 and type 5 17 beta-hydroxysteroid dehydrogenases (17 beta-HSDs). However, the efficiency of such a strategy will be optimal only if androst-4-ene-3,17-dione (Delta 4-dione), the precursor of T, does not possess per se agonist activity on the androgen receptor (AR). To determine if the proliferative effect previously observed on AR(+) cells for Delta 4-dione originates from its direct (per se) action on AR or from its transformation into a metabolite, we. started a series of experimentations using the human prostate cancer LNCaP cell line, which expresses a highly sensitive AR. By real-time RT-PCR analysis, we detected type 1 5(x-reductase (5 alpha-R), a small amount of type 5 17 beta-HSD, but not type 2 5 alpha-R nor type 3,17 beta-HSD. We then studied the transformation of labeled Delta 4-dione in LNCaP cells after 1-7 days and the most important metabolite detected was 5 alpha-androstane-3,17-dione (A-dione), which is the product of 5a-R activity. We measured only low levels of androsterone (ADT) and epi-ADT. This result was next confirmed by using an inhibitor of 5 alpha-R that completely inhibited the transformation of Delta 4-dione into A-dione, and consequently into ADT and epi-ADT. The proliferative effect of Delta 4-dione (carefully purified) on LNCaP (AR(+)) cells was next determined in presence or absence of the 5 alpha-R inhibitor. Although the cells proliferate in the presence of Delta 4-dione only, no cell proliferation was observed with a combination of Delta 4-dione and 5 alpha-R inhibitor, suggesting that A4-dione is not androgenic per se. We next determined that A-dione and epi-ADT stimulated cell growth with the same pattern and potency as Delta 4-dione, whereas ADT had a 3.5-fold lower proliferative activity. in conclusion, Delta 4-dione is not in itself an agonist steroid on LNCaP (AR(+)) cells, and its proliferative activity appears to be mediated by its transformation into A-dione and/or into epi-ADT. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:266 / 271
页数:6
相关论文
共 36 条
[1]   STRUCTURAL AND BIOCHEMICAL-PROPERTIES OF CLONED AND EXPRESSED HUMAN AND RAT STEROID 5-ALPHA-REDUCTASES [J].
ANDERSSON, S ;
RUSSELL, DW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (10) :3640-3644
[2]   DELETION OF STEROID 5-ALPHA-REDUCTASE 2-GENE IN MALE PSEUDOHERMAPHRODITISM [J].
ANDERSSON, S ;
BERMAN, DM ;
JENKINS, EP ;
RUSSELL, DW .
NATURE, 1991, 354 (6349) :159-161
[3]   BINDING OF [H-3] METHYLTRIENOLONE (R 1881) IN RAT PROSTATE AND HUMAN BENIGN PROSTATIC HYPERTROPHY (BPH) [J].
ASSELIN, J ;
LABRIE, F ;
GOURDEAU, Y ;
BONNE, C ;
RAYNAUD, JP .
STEROIDS, 1976, 28 (04) :449-459
[4]   STIMULATORY EFFECTS OF ANDROGENS, ESTROGENS, PROGESTINS, AND DEXAMETHASONE ON THE GROWTH OF THE LNCAP HUMAN PROSTATE-CANCER CELLS [J].
BELANGER, C ;
VEILLEUX, R ;
LABRIE, F .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 595 :399-402
[5]  
Bonkhoff H, 1996, PROSTATE, V29, P261, DOI 10.1002/(SICI)1097-0045(199610)29:4<261::AID-PROS7>3.0.CO
[6]  
2-E
[7]   Expression of different 17 beta-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells [J].
Castagnetta, LAM ;
Carruba, G ;
Traina, A ;
Granata, OM ;
Markus, M ;
PavoneMacaluso, M ;
Blomquist, CH ;
Adamski, J .
ENDOCRINOLOGY, 1997, 138 (11) :4876-4882
[8]   Partial agonist/antagonist properties of androstenedione and 4-androsten-3β,17β-diol [J].
Chen, F ;
Knecht, K ;
Leu, C ;
Rutledge, SJ ;
Scafonas, A ;
Gambone, C ;
Vogel, R ;
Zhang, H ;
Kasparcova, V ;
Bai, C ;
Harada, S ;
Schmidt, A ;
Reszka, A ;
Freedman, L .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 91 (4-5) :247-257
[9]  
DELAUNOIT Y, 1991, CANCER RES, V51, P5165
[10]   Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase [J].
Dufort, I ;
Rheault, P ;
Huang, XF ;
Soucy, P ;
Luu-The, V .
ENDOCRINOLOGY, 1999, 140 (02) :568-574